Cargando…

ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation

Detalles Bibliográficos
Autores principales:	Kaba, Riyaz A, Ahmed, Omar, Cannie, Douglas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bloomsbury Qatar Foundation Journals 2013
Materias:	Lessons from the Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991206/ https://www.ncbi.nlm.nih.gov/pubmed/24749107 http://dx.doi.org/10.5339/gcsp.2013.41

Ejemplares similares

RAAFT-2: Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation
por: Kaba, Riyaz A, et al.
Publicado: (2014)

ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation
por: ElMaghawry, Mohamed
Publicado: (2015)

DECAAF: Emphasizing the importance of MRI in AF ablation
por: ElMaghawry, Mohamed, et al.
Publicado: (2015)

Diabetes and silent atrial fibrillation: A dangerous liaison?
por: Al Suwaidi, Jassim
Publicado: (2014)

FIRE AND ICE: The quest for the perfect modality in atrial fibrillation ablation
por: Sayed, Mohamed, et al.
Publicado: (2016)

CTS Trials Network: Surgical ablation of atrial fibrillation during mitral valve surgery - many questions unanswered
por: Afifi, Ahmed
Publicado: (2015)

The heavy LEGACY: Should weight management be part of every atrial fibrillation clinic?
por: Atreya, Auras R., et al.
Publicado: (2015)

CTS trials network: Rate control vs rhythm control for atrial fibrillation after cardiac surgery - Do bitter pills have blessed effects?
por: Afifi, Ahmed
Publicado: (2016)

INVICTUS: Vitamin K antagonists remain the standard of care for rheumatic heart disease-associated atrial fibrillation
por: Kotit, Susy
Publicado: (2023)

RE-ALIGN: First trial of novel oral anticoagulant in patients with mechanical heart valves – The search continues
por: Shazly, Ahmed, et al.
Publicado: (2014)

Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry
por: Said, Karim
Publicado: (2014)

The Prospective Randomized On-X Valve Anticoagulation Clinical Trial (PROACT): Lower is better, but is it good enough?
por: Bouhout, Ismail, et al.
Publicado: (2019)

The RIME trial: Are we closer to the answer of when to repair ischemic mitral regurgitation?
por: Afifi, Ahmed, et al.
Publicado: (2013)

PLATFORM at 90 days: Evaluating the clinical utility of FFRCT
por: Kharabish, Ahmed, et al.
Publicado: (2016)

PCI versus CABG in patients with complex coronary artery disease: Time for reconciliation?
por: ElGuindy, Ahmed M, et al.
Publicado: (2013)

Culprit lesion-only versus complete revascularization in patients with STEMI: Lessons learned from PRAMI, CvLPRIT, and DANAMI-3 PRIMULTI
por: Hassan, Ahmed, et al.
Publicado: (2015)

CTS Trials Network: A paradigm shift in the surgical treatment of moderate ischemic mitral regurgitation?
por: Afifi, Ahmed
Publicado: (2015)

PARIS: A good start for exercise in HFPEF
por: Elamragy, Ahmed A.
Publicado: (2014)

PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients
por: ElGuindy, Ahmed
Publicado: (2016)

HEAT-PPCI: A clear and welcome win for heparin
por: ElGuindy, Ahmed M.
Publicado: (2014)

ALDO-DHF & Paramount
por: ElGuindy, Ahmed M
Publicado: (2013)

TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?
por: ElGuindy, Ahmed M.
Publicado: (2013)

Transfusion Indication Threshold Reduction (TITRe2) trial: When to transfuse and what to give?
por: Afifi, Ahmed, et al.
Publicado: (2015)

STREAM and FAST-MI – Pharmacoinvasive therapy: A continued role for fibrinolysis in the primary PCI era
por: ElGuindy, Ahmed M.
Publicado: (2014)

STREAM at one year: Further evidence supporting a pharmacoinvasive strategy in patients with STEMI
por: ElGuindy, Ahmed M.
Publicado: (2015)

FAME 2: Reshaping the approach to patients with stable coronary artery disease
por: ElGuindy, Ahmed M.
Publicado: (2015)

Radial artery as a second conduit gains momentum: The RAPCO trial
por: Simry, Walid, et al.
Publicado: (2021)

STOP-HF: Expanding the role of HF programs into the community
por: ElMaghawry, Mohamed, et al.
Publicado: (2014)

FAME 2 – The best initial strategy for patients with stable coronary artery disease: Do we have an answer at last?
por: ElGuindy, Ahmed M, et al.
Publicado: (2013)

BLOCK-HF: CRT gains new ground
por: ElGuindy, Ahmed M., et al.
Publicado: (2013)

PARADIGM-HF: Have we achieved a new paradigm in the treatment of heart failure?
por: Bonow, Robert O., et al.
Publicado: (2014)

TASTE: One-year follow-up results
por: Elmahdy, Mahmoud Farouk, et al.
Publicado: (2015)

Response to ‘Lack of reversibility for NOACs’
por: Kaba, Riyaz A, et al.
Publicado: (2014)

TASTE: To aspirate, or not to aspirate, remains a question
por: Elmahdy, Mahmoud Farouk
Publicado: (2014)

STAMPEDE: Bariatric surgery gains more evidence based support
por: Al Suwaidi, Jassim
Publicado: (2014)

TAVI: New trials and registries offer further welcome evidence – U.S. CoreValve, CHOICE, and GARY
por: Pighi, Michele, et al.
Publicado: (2014)

SYMPLICITY HTN 3: The death knell for renal denervation in hypertension?
por: Patel, Hitesh C, et al.
Publicado: (2014)

CADUCEUS, SCIPIO, ALCADIA: Cell therapy trials using cardiac-derived cells for patients with post myocardial infarction LV dysfunction, still evolving
por: Yacoub, Magdi H, et al.
Publicado: (2013)

TRIOLOGY ACS: No benefit/No harm
por: Elmahdy, Mahmoud Farouk, et al.
Publicado: (2013)

ARCTIC: Additional proof against antiplatelet adjusted therapy
por: Elmahdy, Mahmoud Farouk, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_9ld2509509r2nbl4les98r7o6j